130
Participants
Start Date
April 11, 2017
Primary Completion Date
May 4, 2022
Study Completion Date
May 4, 2022
Riociguat
Riociguat 0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg three times a day for 12 weeks
Placebo
Matching placebo to riociguat 0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg three times a day for 12 weeks
Albert Einstein University/ Montefiore Medical Center, The Bronx
New York Presbyterian Brooklyn Methodist Hospital, Brooklyn
UPMC Division of Hematology and Oncology, Pittsburgh
Howard University, Washington D.C.
Johns Hopkins University, Baltimore
Virginia Commonwealth University Medical Center, Richmond
Duke University, Durham
East Carolina University, Greenville
Medical University of South Carolina, Charleston
Emory University School of Medicine, Atlanta
University of Miami, Miami
University of Tennessee Health Science Center, Memphis
Ohio State University, Columbus
Indiana University, Indianapolis
University of Illinois, Chicago, Chicago
Tulane University, New Orleans
University of Texas Southwestern, Dallas
UCSF Benioff Children's Hospital Oakland, Oakland
Boston University Medical Center, Boston
UNC Comprehensive Sickle Cell Center, Chapel Hill
Mark Gladwin
OTHER